Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B — La Crosse, Wisconsin

Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B is a clinical research site located in La Crosse, Wisconsin, United States 54601.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B has participated in 1 clinical trials.

Therapeutic areas: Meningococcal Infections.

Sponsors: Novartis Vaccines.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in La Crosse

Browse all research sites in Wisconsin · View every site in La Crosse

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B?

Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B conducted?

Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B has 1 clinical trials on record. Their work covers Meningococcal Infections.

Is Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B accredited by Crixeo Clinical Trials?

Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.